This article is more than 5 years old. Information may no longer be current.

OccuLogix acquires Solx

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TORONTO — OccuLogix Inc. has completed its acquisition of Solx Inc., a Boston-based company developing novel glaucoma treatments, according to a press release.

Under the merger terms, Solx is now a wholly owned subsidiary of OccuLogix. Doug Adams, Solx's president and chief executive officer, joins OccuLogix as president of the new subsidiary, according to the release.

Products developed by Solx include the DeepLight 790 titanium sapphire laser and the DeepLight Gold Micro-Shunt. The devices can be used separately or together to reduce IOP in glaucoma patients, according to the company. Both products are currently approved in Europe, and Solx is conducting two randomized, multicenter studies for regulatory approval of the devices in the United States.